Literature DB >> 6336643

Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years.

A S Fauci, B F Haynes, P Katz, S M Wolff.   

Abstract

Eighty-five patients with Wegener's granulomatosis were studied for 21 years at the National Institutes of Health. Patients were treated with a protocol consisting of cyclophosphamide, 2 mg/kg body weight d, together with prednisone, 1 mg/kg body weight d, followed by conversion of the prednisone to an alternate-day regimen. Complete remissions were achieved in 79 of 85 patients (93%). The mean duration of remission for living patients was 48.2 (+/- 3.6) months. Twenty-three patients are off all therapy for a mean duration of 35.3 (+/- 6.3) months without therapy. This study provides a prospective experience with Wegener's granulomatosis and shows that long-term remissions can be induced and maintained in an extremely high number of patients by the combination of daily cyclophosphamide and alternate-day prednisone therapy.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6336643     DOI: 10.7326/0003-4819-98-1-76

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  295 in total

1.  Monocyte activation in patients with Wegener's granulomatosis.

Authors:  A C Muller Kobold; C G Kallenberg; J W Tervaert
Journal:  Ann Rheum Dis       Date:  1999-04       Impact factor: 19.103

2.  Pulmonary Wegener's granulomatosis misdiagnosed as malignancy.

Authors:  S Uppal; N Saravanappa; J P Davis; C K Farmer; D J Goldsmith
Journal:  BMJ       Date:  2001-01-13

Review 3.  Immunosuppression in uveitis therapy.

Authors:  R N Van Gelder; H J Kaplan
Journal:  Springer Semin Immunopathol       Date:  1999

Review 4.  Rare diseases.3: Wegener's granulomatosis.

Authors:  C A Langford; G S Hoffman
Journal:  Thorax       Date:  1999-07       Impact factor: 9.139

Review 5.  Small vessel vasculitis of the lung.

Authors:  M I Schwarz; K K Brown
Journal:  Thorax       Date:  2000-06       Impact factor: 9.139

Review 6.  Pathogenesis and treatment of ANCA-associated systemic vasculitis.

Authors:  A D Salama
Journal:  J R Soc Med       Date:  1999-09       Impact factor: 5.344

Review 7.  TAP deficiency syndrome.

Authors:  S D Gadola; H T Moins-Teisserenc; J Trowsdale; W L Gross; V Cerundolo
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

Review 8.  Combination therapy in autoimmune disease: vasculitis.

Authors:  D Carruthers; P Bacon
Journal:  Springer Semin Immunopathol       Date:  2001

Review 9.  Wegener's granulomatosis and the Churg-Strauss syndrome.

Authors:  J L Faul; W G Kuschner
Journal:  Clin Rev Allergy Immunol       Date:  2001-08       Impact factor: 8.667

10.  Amphipathic variable region heavy chain peptides derived from monoclonal human Wegener's anti-PR3 antibodies stimulate lymphocytes from patients with Wegener's granulomatosis and microscopic polyangiitis.

Authors:  E Peen; C Malone; C Myers; R C Williams; A B Peck; E Csernok; W L Gross; R Staud
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.